Clinical Scorecard: Evaluation of Tacrolimus in Ulcerative Colitis: A Retrospective Analysis of Factors Influencing Remission Induction and Maintenance

At a Glance

Key Highlights

• Tacrolimus achieves approximately 50% remission induction rate in UC patients.
• Maintenance therapy often involves azathioprine, but adverse events can limit its use.
• Relapse rates after TAC-induced remission remain high, with 30-40% requiring colorectal resection within 52 weeks.

Guideline-Based Recommendations

Diagnosis

• Use Lichtiger Colitis Activity Index (LCAI) to define remission (score ≤4 at 4 weeks post-TAC initiation).
• Assess endoscopic severity with Mayo endoscopic score and UCEIS.

Management

• Induce remission with TAC targeting trough blood concentrations of 10–15 ng/mL initially, then 5–10 ng/mL for maintenance.
• Maintain remission with single-agent therapy: TAC, AZA, or biologic agents depending on patient tolerance and history.
• Monitor and adjust TAC dosing based on trough blood levels every other day until target concentration is achieved.

Monitoring & Follow-up

• Regular blood sampling to monitor TAC trough concentrations during induction and maintenance phases.
• Monitor for adverse events related to AZA, including cytopenia, hepatic disorders, and alopecia.
• Evaluate clinical response and endoscopic scores periodically to assess remission status.

Risks

• High relapse rate post-TAC remission induction, with 30-40% undergoing colorectal resection within 52 weeks.
• AZA-associated serious adverse events including cytopenia and hepatic disorders; genetic testing for NUDT15 may reduce severe AEs but not predict mild/moderate events.
• Potential need to switch maintenance therapy to biologics if relapse or AZA intolerance occurs.

Patient & Prescribing Data

136 UC patients treated with TAC from 2009 to 2021; 99 patients followed for remission maintenance at 52 weeks.

TAC induction achieves remission in ~50% of patients; maintenance therapy choice (TAC, AZA, biologics) impacts remission sustainability; monitoring trough TAC levels critical for dose adjustment.

Clinical Best Practices

• Initiate TAC induction therapy with close monitoring of trough blood levels to achieve target concentrations promptly.
• Define remission using standardized clinical indices (LCAI ≤4) and confirm with endoscopic evaluation.
• Use single-agent maintenance therapy tailored to patient history and tolerance, avoiding concomitant AZA with TAC or biologics.
• Screen for NUDT15 variants before AZA initiation to reduce risk of severe adverse events.
• Monitor patients closely for relapse signs and adjust maintenance therapy accordingly, including switching to biologics if needed.

References

• Global increase in UC cases
• Newer drugs and treatment options for UC
• Tacrolimus dosing and target concentrations
• Comparison of TAC and infliximab for remission induction
• Colorectal resection rates post-TAC remission
• Azathioprine for maintenance therapy in UC
• Effectiveness of AZA maintenance therapy
• Adverse events associated with AZA
• NUDT15 gene and AZA adverse events
• Lichtiger Colitis Activity Index (LCAI)
• Mayo endoscopic score
• Ulcerative Colitis Endoscopic Index of Severity (UCEIS)